Filing Flows › Protagonist Therapeutics (PTGX) › Q3 2026 › vs Q3 2025
Protagonist Therapeutics (PTGX) Q3 2026 vs Q3 2025 (year over year)
Protagonist Therapeutics's revenue rose $270M (58×) from $4.7M in Q3 2025 to $274M in Q3 2026. Operating margin 79.6% against -985.2% (+1064.7 pts).
Protagonist Therapeutics, Q3 2026: revenue $274M (58× year over year), operating margin 79.6%, net earnings $220M, operating cash flow −$23.2M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 79.6% | -985.2% | +1064.7 pts |
| Net margin | 80.2% | -834.9% | +915.0 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $274M | $4.7M | $270M | 58× |
| Other income, net | $8.2M | $7.1M | $1.2M | +16% |
| Operating profit | $218M | −$46.4M | $265M | — |
| Costs & expenses | $56.1M | $51.1M | $4.9M | +10% |
| Pre-tax earnings | $227M | −$39.3M | $266M | — |
| Research & development | $41.3M | $40.0M | $1.3M | +3% |
| General & admin | $13.7M | $11.1M | $2.6M | +23% |
| Net earnings | $220M | −$39.3M | $259M | — |
| Income tax | $6.6M | $0 | $6.6M | — |
| Operating cash sources | $258M | −$26.5M | $284M | — |
| Depreciation & amortization | $409K | $361K | $48K | +13% |
| Share-based compensation | $14.4M | $10.6M | $3.8M | +36% |
| Cash used in operations | $23.2M | $1.9M | $21.3M | 12× |
| Working capital & other | $258M | −$26.5M | $284M | — |
Questions
How much did Protagonist Therapeutics's revenue grow year over year in Q3 2026?
Protagonist Therapeutics's revenue rose $270M (58×) from $4.7M in Q3 2025 to $274M in Q3 2026. Operating margin 79.6% against -985.2% (+1064.7 pts).